Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2025-013901 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Anna-Sophia Mast und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Pediatrics, Hematology and Oncology, University Hospital Tübingen, Tübingen, Germany. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Antigens, CD19, Receptors, Chimeric Antigen, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Hospital Tuebingen, Miltenyi Biotec.
Abstract (Originalsprache)
Background
CD19-directed chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment landscape for pediatric B-cell acute lymphoblastic leukemia (B-ALL), yet relapses driven by antigen escape remain a major limitation. Dual-targeting CAR approaches recognizing CD19 and CD22 have shown promising clinical activity, but sustained remissions are limited by insufficient CAR T-cell persistence.
Methods
CAR22.19, a fully human tandem CD19/CD22 CAR, was developed and administered under a named-patient program to nine heavily pretreated pediatric patients with relapsed or refractory B-ALL. Treatment indications were CD19-negative blast population (n=5), relapse after CD19 CAR T (n=3) and/or restricted access to approved CAR T-cell products (n=3). Autologous and donor-derived CAR22.19 T-cells (CART22.19) were manufactured using a good manufacturing practice-compliant, semiautomated fresh-in-fresh-out process. Safety and efficacy were assessed through standardized clinical monitoring, measurable residual disease analysis, and CAR T-cell kinetics.
Results
Preclinical validation demonstrated antigen-specific cytotoxicity and dual antigen activity. Clinically, CART22.19 were well tolerated, with no treatment-related deaths and no grade ≥3 neurotoxicity, while grade ≥3 cytokine release syndrome occurred in 38.5% (5/13) of infusions and resolved with standard interventions. An initial complete molecular remission was achieved in 78% (7/9) of patients, with a 12-month overall survival rate of 55.6% (95% CI, 20.4-80.5%). Complete remission in CD19⁻CD22⁺ disease underscores the functional contribution of the CD22-targeting domain, whereas all patients refractory to prior CD19 CAR T-cell therapy relapsed early despite retained CD19⁺CD22⁺ expression. Limited in vivo persistence may represent a contributing factor to treament failure. Notably, durable remission and sustained functional persistence of CART22.19 was achieved in one patient refractory to autologous CART22.19 following infusion of donor-derived CART22.19 after reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (alloHSCT) in nonremission.
Conclusions
CART22.19 therapy demonstrated a favorable safety profile and promising clinical activity in a high-risk pediatric population, with dual targeting enabling disease control in CD19-negative leukemia. Nonetheless, limited CAR T-cell persistence may represent an important obstacle to sustained remission. Our findings support further clinical development of CART22.19 and indicate that donor-derived CAR T-cells following RIC alloHSCT may represent a potential therapeutic strategy to enhance persistence and improve outcomes in heavily pretreated pediatric patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Pediatrics, Hematology and Oncology, University Hospital Tübingen, Tübingen, Germany.
- Department of General Pediatrics, Hematology and Oncology, University Hospital Tübingen, Tübingen, Germany peter.lang@med.uni-tuebingen.de.
- Excellence cluster iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University Hospital Tübingen, Tübingen, Germany.
- German Cancer Research Consortium (DKTK), Partner Site Tübingen, German Cancer Research Center, Heidelberg, Germany.
- Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.
- Leibniz Institute for Immunotherapy, Regensburg, Germany.
Förderung
- University Hospital Tuebingen
- Miltenyi Biotec
Zitieren
APA
Mast, A. S., Lang, P., Schlegel, P., Calkoen, F. G., Atar, D., Scheuermann, S., Klein, S., Braun, C., Schinle, F., Schmidt, M., Hensen, L., Ebinger, M., Döring, M., Schäfer, J. F., Schulte, J., Bethge, W. A., Lengerke, C., Alahmari, B., Hu, P., …, & Seitz, C. M. (2026). Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013901
Vancouver
Mast AS, Lang P, Schlegel P, Calkoen FG, Atar D, Scheuermann S, et al. Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-013901
BibTeX
@article{Mast2026,
author = {Mast, Anna-Sophia and Lang, Peter and Schlegel, Patrick and Calkoen, Friso G and Atar, Daniel and Scheuermann, Sophia and Klein, Sylvia and Braun, Christiane and Schinle, Florian and Schmidt, Marina and Hensen, Luca and Ebinger, Martin and Döring, Michaela and Schäfer, Jürgen F and Schulte, Johannes and Bethge, Wolfgang A and Lengerke, Claudia and Alahmari, Bader and Hu, Peirong and Schneider, Dina and Orentas, Rimas J and Handgretinger, Rupert and Seitz, Christian Martin},
title = {Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2025-013901}
}
EUVIMED